51035-17-7Relevant articles and documents
CARBAZOLE ALKALOIDS FROM CLAUSENA LANSIUM
Li, Wen-Shyong,McChesney, James D.,El-Feraly, Farouk S.
, p. 343 - 346 (1991)
Three new carbazole alkaloids, 3-formyl-6-methoxycarbazole, methyl 6-methoxycarbazole-3-carboxylate and 3-formyl-1,6-dimethoxycarbazole and two carbazole derivatives, 3-formyl carbazole and methyl carbazole-3-carboxylate, reported for the first time from Nature, have been isolated from the root of Clausena lansium along with three previously reported carbazole alkaloids, murrayanine, glycozoline and indizoline.All isolated compounds except glycozoline have a carbonyl group at C-3 with different substitution patterns at C-1, C-2 and C-6.
Discovery of carbazole carboxamides as novel RORγt inverse agonists
Huang, Yafei,Yu, Mingcheng,Sun, Nannan,Tang, Ting,Yu, Fazhi,Song, Xiaoxia,Xie, Qiong,Fu, Wei,Shao, Liming,Wang, Yonghui
, p. 465 - 476 (2018/02/28)
A novel series of carbazole carboxamides was discovered as potent RORγt inverse agonists using a scaffold hybridization strategy. Structure-activity relationship exploration on the amide linker, carbazole ring and arylsulfone moiety of the hybrid amide 3a led to identification of potent RORγt inverse agonists. Compound 6c was found to have a good RORγt activity with an IC50 of 58.5 nM in FRET assay, and reasonable inhibitory activity in mouse Th17 cell differentiation assay (58.8% inhibition at 0.3 μM). The binding mode of carbazole carboxamides in RORγt ligand binding domain was discussed.
FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS
-
Page/Page column 32, (2016/02/26)
The present invention relates to anti-tropomyosin compounds, processes for their preparation, and methods for treating or preventing a disease or disorder, such as a proliferative disease (preferably cancer), using compounds of the invention.
Mastering tricyclic ring systems for desirable functional cannabinoid activity
Petrov, Ravil R.,Knight, Lindsay,Chen, Shao-Rui,Wager-Miller, Jim,McDaniel, Steven W.,Diaz, Fanny,Barth, Francis,Pan, Hui-Lin,Mackie, Ken,Cavasotto, Claudio N.,Diaz, Philippe
, p. 881 - 907 (2013/11/19)
There is growing interest in using cannabinoid receptor 2 (CB2) agonists for the treatment of neuropathic pain and other indications. In continuation of our ongoing program aiming for the development of new small molecule cannabinoid ligands, we have synthesized a novel series of carbazole and γ-carboline derivatives. The affinities of the newly synthesized compounds were determined by a competitive radioligand displacement assay for human CB2 cannabinoid receptor and rat CB1 cannabinoid receptor. Functional activity and selectivity at human CB1 and CB2 receptors were characterized using receptor internalization and [35S]GTP-γ-S assays. The structure-activity relationship and optimization studies of the carbazole series have led to the discovery of a non-selective CB1 and CB2 agonist, compound 4. Our subsequent research efforts to increase CB2 selectivity of this lead compound have led to the discovery of CB2 selective compound 64, which robustly internalized CB2 receptors. Compound 64 had potent inhibitory effects on pain hypersensitivity in a rat model of neuropathic pain. Other potent and CB2 receptor-selective compounds, including compounds 63 and 68, and a selective CB1 agonist, compound 74 were also discovered. In addition, we identified the CB2 ligand 35 which failed to promote CB2 receptor internalization and inhibited compound CP55,940-induced CB2 internalization despite a high CB2 receptor affinity. The present study provides novel tricyclic series as a starting point for further investigations of CB2 pharmacology and pain treatment.